LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
